Skip to main content

Incannex appoints principal investigators for pivotal IHL-42X trial

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The investigators, Dr John D Hudson of FutureSearch Trials of Neurology in Austin, Texas, and Dr Russell Rosenberg of Neurotrials Research Inc in Atlanta, Georgia, will play a crucial role overseeing the first clinical trial sites, handling submissions to the FDA and obtaining ethics approval from Institutional Review Boards.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.